Seeking Alpha

Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th ...

SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor ...
Seeking Alpha

Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy at IASLC 2023 World Conference on Lung Cancer

SAN CARLOS, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor ...
Healio

Guidelines: Toxicity management vital with tumor-infiltrating lymphocytes

Please provide your email address to receive an email when new articles are posted on . Clinicians should have a low threshold for stopping interleukin-2 when treating with tumor-infiltrating ...